The overall response rate (ORR) was 63% in CLL/SLL (79% in those with 17p- or TP53 mutation), 52% in MCL, 68% in WM and 50% in follicular lymphoma (FL). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.